Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634435 · ClinicalTrials.gov registry record · Phase 1
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
A Phase 1 study, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04634435 is a Phase 1 study that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 7 participants.
The verdict
NCT04634435, a Phase 1 study, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting in MM patients with minimal residual disease (MRD+) in first or second remission.
Interventions
- COMBINATION_PRODUCT BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-10-21 |
| Est. Completion | 2025-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634435
The ClinicalTrials.gov registry entry for NCT04634435 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 is the first listed.
NCT04634435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04634435 about?
NCT04634435 is a clinical study titled "Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients". This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting ...
What is the current status of trial NCT04634435?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-10-21. Estimated completion is 2025-01-10.
What interventions are being tested in trial NCT04634435?
The interventions under investigation include: BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04634435?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.